Sentence examples for agents with standard from inspiring English sources
Several challenges remain, including finding ways of targeting these agents specifically to tumors (sparing normal cells), and the development of rationales for combining these new agents with standard therapies and for prioritizing the development of an overwhelming number of novel small molecules targeting cell cycle and apoptosis.
The most promising combinations of anti-angiogenic agents with standard chemotherapy also require further exploration.
There is considerable interest in combining novel targeted agents with standard chemotherapeutics to enhance efficacy.
These methodologies will be more important as ongoing studies are now assessing more combinations of targeted agents with standard chemotherapy as well as combinations of targeted agents.
Although it may not be feasible to combine some of these agents with standard chemotherapy, the potential remains to increase the duration of disease-free survival by using these agents as a consolidation/maintenance monotherapy after tumour control has been achieved with standard treatment modalities.
Thus, combining an active antiangiogenic agent with standard chemotherapy may potentially improve tumour control and provide sustained benefit.
Major databases were searched for randomised studies of mCRC after first-line treatment comparing (1) standard treatment plus biologic agent with standard treatment or (2) standard treatment with biologic agent with the same treatment with different biologic agent(s).
Seven (46.6%) patients received an anti-TNF agent along with standard immunosuppressive agents.
Anthracyclines and taxanes are considered the most active drugs for the treatment of metastatic breast cancer (MBC) [ 1, 2], and combination regimens of these agents compared with standard anthracycline-containing chemotherapy in phase III randomized trials [ 3- 9] have shown a higher activity (range of improvement 5 38%) of the former.
In taking the latter step, Orza said, the union will provide agents with a standard form to detail their fees, which they will give to their clients and the union.
Other mAb combinations are currently being investigated, and are detailed in Table 2. Another strategy is to combine checkpoint agents with other standard or investigational anticancer therapies including radiotherapy, cytotoxic chemotherapy, targeted therapies, or vaccine/cytokine therapy.
